HUMACYTE INC (HUMA) Stock News
NASDAQ:HUMA - Nasdaq - US44486Q1031 - Common Stock - Currency: USD
HUMA Latest News, Press Relases and Analysis
There are notable gap-ups and gap-downs in today's session.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.
Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq
DURHAM, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally...
Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of 47.37% and 2.45%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: IRD
Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update
- Commenced market launch and first commercial sales of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma -...
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025
DURHAM, N.C., May 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally...
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know
The latest trading day saw Humacyte, Inc. (HUMA) settling at $1.45, representing a +1.4% change from its previous close.
All You Need to Know About Humacyte, Inc. (HUMA) Rating Upgrade to Buy
Humacyte, Inc. (HUMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Humacyte, Inc. (HUMA) Ascends But Remains Behind Market: Some Facts to Note
Humacyte, Inc. (HUMA) reachead $1.48 at the closing of the latest trading day, reflecting a +0.68% change compared to its last close.
Humacyte, Inc. (HUMA) Increases Despite Market Slip: Here's What You Need to Know
Humacyte, Inc. (HUMA) reachead $1.55 at the closing of the latest trading day, reflecting a +0.65% change compared to its last close.
Lululemon reports Q4 beat, CoreWeave IPO priced at $40: Morning Buzz
The major indexes were sharply lower near noon as investors react to the release of key inflation data and recent trade policy developments. The Federal Reserve’s key inflation measure, the core personal consumption expenditures price index, showed a 0.4% increase for the month of February, putting the 12-month inflation rate at a hotter-than-expected 2.8%. Looking to commodities, gold prices are fractionally higher, continuing their rally and bringing the record price to above $3,100. Meanwhile
Braze price target raised to $55 from $50 at Citi
Citi raised the firm’s price target on Braze (BRZE) to $55 from $50 and keeps a Buy rating on the shares after the company “delivered a strong finish to FY25” and gave FY26 organic growth guidance of 16%, which does not include the contribution from the OfferFit acquisition, that was better-than-expected. The company also announced it will acquire AI decisioning-engine startup OfferFit, which tripled revenue last year, leading the firm to “believe there is healthy room for upside to numbers,” th
Humacyte price target lowered to $8 from $10 at BTIG
BTIG lowered the firm’s price target on Humacyte (HUMA) to $8 from $10 and keeps a Buy rating on the shares post the Q4 report. The firm cites the company’s increased share count for the target cut. The analyst views Humacyte’s early commercial traction as evidence of the “game-changing nature” of its Acellular Tissue Engineered Vessel. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >>
Lulu’s Fashion Lounge price target lowered to $1 from $2 at Telsey Advisory
Telsey Advisory analyst Dana Telsey lowered the firm’s price target on Lulu’s Fashion Lounge (LVLU) to $1 from $2 and keeps a Market Perform rating on the shares. The company delivered an EBITDA beat for Q4, driven by better-than-expected gross margin performance and tighter expense control, the analyst tells investors. While the firm is encouraged by the company’s FY25 outlook for its adjusted EBITDA, the challenged topline hinders a more robust turnaround, the firm adds. Published first on The
U.S. Bancorp price target lowered to $56 from $62 at Wells Fargo
Wells Fargo lowered the firm’s price target on U.S. Bancorp (USB) to $56 from $62 and keeps an Overweight rating on the shares as part of a Q1 earnings preview for the large-cap banks. The firm is bullish on the sector on a one-year view citing the “biggest deregulation in three decades,” but note that Q1 outlooks “may be tricky” given policy uncertainties. Wells reduced estimates by 4% for Q1 and 2% through 2027. The key reason is a “degree of paralysis” from policy uncertainty that makes Wells
Humacyte Stock Continues Slide Despite Lower Than Expected Q4 Loss – But Retail Gets More Bullish
Fourth-quarter loss per share came in at $0.16, lower than the $0.24 in the corresponding period of 2023, and below the consensus estimate of $0.25, according to FinChat data.
Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
- Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular...
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally...